LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
Healthcare
$3.34 -6.62%
-$0.42 today
- Market cap
- $104.94M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
52W Low $5.85High $50.40
Volume 0.64M
Average 0.89M
Income Statement
Follow revenue through to earnings.
Revenue
$19.09M
FY 2025 · Annual
Operating Income
-$91.14M
FY 2025 · Annual
Net Income
-$82.13M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15M | 0 | 0 | 19.09M |
| Cost of Revenue | 734K | 0 | 0 | 58K | 705K |
| Gross Profit | (734K) | 15M | 0 | (58K) | 18.38M |
| Gross Margin | — | 100.0% | — | — | 96.3% |
| Research & Development | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M |
| Selling, General & Admin | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M |
| Operating Expenses | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M |
| Depreciation & Amortization | 734K | 8K | 15K | 58K | 287K |
| EBITDA | (70.03M) | (10.46M) | (70.13M) | (49.71M) | (81.34M) |
| EBITDA Margin | — | -69.7% | — | — | -426.1% |
| Operating Income | (60.44M) | (10.48M) | (72.43M) | (58.61M) | (91.14M) |
| Operating Margin | — | -69.9% | — | — | -477.5% |
| Interest Income | 0 | 0 | 2.19M | 8.55M | 9.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (10.32M) | 19K | 2.28M | 8.84M | 9.51M |
| Income Before Tax | (70.76M) | (10.46M) | (70.15M) | (49.77M) | (81.63M) |
| Pre-Tax Margin | — | -69.8% | — | — | -427.6% |
| Income Tax Expense | 0 | 347K | (179K) | 1K | 502K |
| Net Income | (70.76M) | (10.81M) | (69.97M) | (49.77M) | (82.13M) |
| Net Margin | — | -72.1% | — | — | -430.3% |
| EPS (Basic) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| EPS (Diluted) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| 8.29M | 7.84M | 8.15M | 21.28M | 28.81M | |
| 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
LENZ Earnings Waterfall · TTM
NASDAQ:LENZ · Revenue to Net Income
Key Ratios
EPS$-3.60
Gross Margin75.8%
Net Margin-1218.7%
P/E Ratio-9.7
P/S Ratio183.7
Analysis
$21.0M of revenue converted into -$109.0M of net income for the selected period. Gross margin is 75.8% and net margin is -1218.7%, showing how much revenue survives after costs and taxes. EPS is $-3.60, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| SC 13G | SC 13G filing | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 |
How much revenue does LENZ generate?
LENZ Therapeutics, Inc. (LENZ) reported $19.09M of revenue in fiscal 2025.
Is LENZ profitable?
LENZ Therapeutics, Inc. (LENZ) reported -$82.13M of net income, with a net margin of -430.3%.
Continue the stock analysis
Jump to another research area for this company.